-
公开(公告)号：KR101760239B1
公开(公告)日：2017-07-24
申请号：KR1020100124510
申请日：2010-12-07
Applicant: (주)차바이오텍
IPC: C12Q1/24 , C12N5/0775
Abstract: 본발명은배아줄기세포로부터중간엽세포를분리, 배양하는방법에관한것으로, 더욱상세하게는세포배양삽입체를이용하여다분화능력을가진중간엽세포를효과적으로분리, 배양하는방법및 상기방법에의해분리된중간엽세포에관한것이다. 본발명의분리방법은다른물질의첨가없이세포배양삽입체만을이용하여배아발생중 일어나는현상을시험관내에서자연스럽게유도하여, 배아줄기세포로부터중간엽줄기세포를포함한중간엽세포를저비용으로, 단시간에효과적으로분리, 배양하는방법이다.
Abstract translation: 本发明分离的间充质细胞，一种用于培养，更特别是细胞有效地通过使用培养插管，培养物的方法和从胚胎干细胞的方法的与分化能力的间充质细胞中分离 由本发明的分离涉及间充质细胞。 以较低的成本，本发明的分离方法的间充质细胞，包括仅使用一个细胞培养插管在不添加其他物质自然体外生成胚胎，胚胎干细胞，的现象在短时间内充质干细胞从通过感应 有效地分离和培养细胞。
-
公开(公告)号：KR101751957B1
公开(公告)日：2017-06-30
申请号：KR1020100105000
申请日：2010-10-27
CPC classification number: B82Y5/00 , C12N5/00 , C12N2506/00 , C12N2531/00
Abstract: 본발명은 (a) 산화실리콘(silicon dioxide) 층을갖는나노튜브(nanotube)에역분화전사인자를결합시켜, 전사인자-나노튜브운반체를제작하는단계; (b) 상기전사인자-나노튜브운반체를세포와함께배양하는단계; 및 (c) 단계(b)로부터얻어진배양물로부터배아줄기세포-유사콜로니(embryonic stem cell-like colonies)를분리하는단계를포함하는, 세포의역분화방법을제공한다. 본발명에따른제조방법은바이러스벡터를사용함으로써야기될수 있는안전성문제(예를들어, 암세포의진행가능성등)를근본적으로회피할수 있다. 또한, 단백질의변성을막으면서, 나노튜브운반체로부터단백질이지속적으로방출되므로, 단백질을반복적으로처리하지않고도충분한양의단백질을공급할수 있다.
Abstract translation: （A）通过结合具有二氧化硅层的纳米管特异性转录因子来制备转录因子 - 纳米管载体; （b）用细胞培养转录因子 - 纳米管载体; 并且（c）从步骤（b）获得的培养物中分离胚胎干细胞样集落。 根据本发明的制造方法可以从根本上避免可能由使用病毒载体引起的安全问题（例如，癌细胞的进展等）。 另外，由于蛋白质从纳米管载体不断释放，同时抑制蛋白质变性，因此可以供应足够量的蛋白质而无需重复处理蛋白质。
-
13.发明授权제대혈 줄기세포 유래 혈관전구세포 배양액 또는 배양 분비물을 이용한 피부재생용 조성물 및 이의 용도 有权通过使用脐带血衍生的内皮祖细胞（CB-EPC）的中等或分泌的皮肤再生的组合物及其用途
公开(公告)号：KR101422453B1
公开(公告)日：2014-07-28
申请号：KR1020090033249
申请日：2009-04-16
Applicant: (주)차바이오텍
Abstract: 본 발명은 제대혈 줄기세포 유래 혈관전구세포 배양액 또는 분비물을 이용한 피부재생용 조성물 및 이의 용도에 관한 것으로, 본 발명은 제대혈 줄기세포 유래 혈관전구세포 자체가 아닌 배양 분비물을 치료제로 이용하므로 세포 이식으로 인한 면역거부반응의 위험성이 없고, 신생혈관 생성능력을 촉진시켜 창상치료에 효과적이며, 이를 화장품 원료로 이용하는 경우 콜라겐 생성을 증대시켜 피부노화를 방지하는 효과를 제공한다. 특히, 상기 배양 분비물을 고농도로 농축시킨 본 발명의 조성물은 높은 창상치료효과를 제공한다.
제대혈 유래 줄기세포, 창상 치료, 제대혈 줄기세포 유래 혈관전구세포 배양 분비물 농축액, 기능성 화장품, 화장료-
公开(公告)号：KR1020130085308A
公开(公告)日：2013-07-29
申请号：KR1020120006371
申请日：2012-01-19
Applicant: (주)차바이오텍 , 차의과학대학교 산학협력단
CPC classification number: C12N5/0692 , A61K35/00 , C12N5/0662 , C12N2501/155 , C12N2506/02 , C12N5/0068 , C12N9/6427 , C12N2501/105 , C12N2501/165 , C12N2533/52 , C12N2533/54
Abstract: PURPOSE: A manufacturing method of a human embryonic stem cell originated pericyte progenitor cell is provided to manufacture a human embryonic stem cell originated pericyte progenitor cell which is able to be useful as a cytotherapy composition for treatment or prevention of cardiovascular diseases or retinal disorders. CONSTITUTION: A manufacturing method of a pericyte progenitor cell from a stem cell comprises 1) a step of treating a stem cell originated embryoid body with a bone morphogenetic protein 4 (BMP4) growth factor to differentiate to a mesodermal cell; 2) a step of isolating the embryoid body including the differentiated mesodermal cell to a single cell; and 3) a step of cultivating the isolated single cell in a petri dish coated with a substrate, and proliferating the attached cells only by natural selection; The stem cell in step 1) is selected from the group consisting of human embryonic stem cell, induced pluripotent stem cell (iPSC) and somatic cell nuclear transfer cell (SCNT). A pharmaceutical composition for prevention and treatment of cardiovascular diseases includes the pericyte progenitor cell as an active ingredient.
Abstract translation: 目的：提供一种人胚胎干细胞产生的周细胞祖细胞的制造方法，用于制造能够用作治疗或预防心血管疾病或视网膜疾病的细胞疗法组合物的源于人胚胎干细胞的周细胞祖细胞。 构成：来自干细胞的周细胞祖细胞的制造方法包括1）用骨形态发生蛋白4（BMP4）生长因子处理源自干细胞的胚状体的步骤，以分化成中胚层细胞; 2）将包括分化的中胚层细胞的胚状体分离成单个细胞的步骤; 和3）在涂覆有底物的陪替氏培养皿中培养分离的单细胞的步骤，并且仅通过自然选择增殖附着的细胞; 步骤1）中的干细胞选自人胚胎干细胞，诱导多能干细胞（iPSC）和体细胞核转移细胞（SCNT）。 用于预防和治疗心血管疾病的药物组合物包括周细胞祖细胞作为活性成分。
-
公开(公告)号：KR1020130043520A
公开(公告)日：2013-04-30
申请号：KR1020110107727
申请日：2011-10-20
Applicant: (주)차바이오텍 , 성균관대학교산학협력단
Abstract: PURPOSE: A method for isolating and proliferating lung cancer cells is provided to effectively isolate and proliferate the lung cancer cells from a patient with lung cancer, and to establish a lung cancer cell line. CONSTITUTION: A method for isolating and proliferating lung cancer cells from a lung cancer tissue comprises: a step of making an incision of a lung cancer tissue from a patient in a diameter of 40-100 micrometers; a step of culturing the lung cancer tissue; a step of isolating lung cancer cells using dispase; a step of culturing the lung cancer cells in a serum-free N2 medium; and a step of culturing the lung cancer cells in a medium containing serum and growth factors.
Abstract translation: 目的：提供肺癌细胞分离和增殖的方法，以有效地从肺癌患者中分离和增殖肺癌细胞，并建立肺癌细胞系。 构成：从肺癌组织分离和增殖肺癌细胞的方法包括：从直径为40-100微米的患者切下肺癌组织的步骤; 培养肺癌组织的一个步骤; 使用分泌酶分离肺癌细胞的步骤; 在无血清N2培养基中培养肺癌细胞的步骤; 以及在含有血清和生长因子的培养基中培养肺癌细胞的步骤。
-
Patent Agency Ranking
公开(公告)号：KR1020120035801A
公开(公告)日：2012-04-16
申请号：KR1020100097543
申请日：2010-10-06
Applicant: (주)차바이오텍
IPC: C12N5/0735 , C12N5/077 , C12N5/02
CPC classification number: C12N5/0657 , A61K35/34 , C12N2506/02
Abstract: PURPOSE: A method for isolating differentiated cardiac muscle cells from human embryonic stem cells is provided to prevent contamination by exogenous blood serum and to develop therapy for treating heart-associated diseases. CONSTITUTION: A method for isolating cardiac muscle cells from human embryonic stem cells comprises: a step of culturing an embryoid body of the human embryonic stem cells in a serum-free medium in a density of 2X10^4 cells/cm^2- 7X10^4 cells/cm^2. The serum-free medium contains DMEM, N2 and antibiotics.
Abstract translation: 目的：提供一种从人类胚胎干细胞中分离分化的心肌细胞的方法，以防止外来血清的污染，并开发治疗心脏相关疾病的治疗方法。 构成：用于从人胚胎干细胞中分离心肌细胞的方法包括：以2×10 4细胞/ cm 2 2- 7×10 -4密度的无血清培养基培养人胚胎干细胞的胚状体的步骤， 4个细胞/ cm ^ 2。 无血清培养基含有DMEM，N2和抗生素。
-
17.发明授权피부줄기세포의 배양방법 및 상기 배양방법으로 얻어진 피부줄기세포를 포함하는 주름개선 또는 발모촉진용 조성물 有权用于培养皮肤干细胞的方法和用于皱纹或促进头发生长的组合物，其包含由该方法获得的皮肤皮肤干细胞
公开(公告)号：KR101026070B1
公开(公告)日：2011-03-31
申请号：KR1020100059065
申请日：2010-06-22
Applicant: (주)차바이오텍 , 주식회사 엘컴사이언스
CPC classification number: C12N5/0625 , A61K8/985 , A61K9/19 , A61Q19/08 , C12N2502/09
Abstract: PURPOSE: A method for culturing skin stem cells in serum-free medium containing diterpene compound isolated from Siegesbeckia is provided to effectively proliferate skin cells and to promote hair growth and anti-wrinkling. CONSTITUTION: A culture of skin stem cells is performed in a serum-free medium containing a compound selected from chemical formulas 3-9. The concentration of the compound is 1-500uM. A composition for anti-wrinkling contains culture of the skin stem cells. The culture is a supernatant obtained by centrifuging culture liquid of the skin stem cells, supernatant, or concentrate of the supernatant.
Abstract translation: 目的：提供一种在含有从Siegesbeckia分离的二萜化合物的无血清培养基中培养皮肤干细胞的方法，以有效增殖皮肤细胞并促进毛发生长和抗皱。 构成：皮肤干细胞的培养在含有选自化学式3-9的化合物的无血清培养基中进行。 化合物的浓度为1-500uM。 抗皱组合物含有皮肤干细胞的培养物。 培养物是通过离心上清液的皮肤干细胞，上清液或浓缩物的培养液而获得的上清液。
-
公开(公告)号：KR101023400B1
公开(公告)日：2011-03-22
申请号：KR1020100003446
申请日：2010-01-14
Applicant: (주)차바이오텍 , 주식회사 엘컴사이언스
IPC: A61K31/122 , A61K36/28 , A61P17/02
Abstract: PURPOSE: A composition containing diterpene with kauran skeleton extracted from Siegesbeckia is provided to ensure wound healing and excellent proliferation and migration abilities. CONSTITUTION: A pharmaceutical composition for wound healing contains a compound selected from chemical formulas 1-9 as an active ingredient. The concentration of the compound is 10-500 uM. The composition is manufactured in the form of liquid, suspension, emulsion, lotion, and ointment. The compound is administered in 1-1000 mg/kg a day.
Abstract translation: 目的：提供含有从Siegesbeckia提取的具有克劳恩骨架的二萜的组合物，以确保伤口愈合和良好的增殖和迁移能力。 构成：用于伤口愈合的药物组合物含有选自化学式1-9的化合物作为活性成分。 化合物的浓度为10-500uM。 组合物以液体，悬浮液，乳液，洗剂和软膏的形式制备。 该化合物每天施用1-1000mg / kg。
-
19.发明公开제대혈 줄기세포 유래 혈관전구세포 배양액 또는 배양 분비물을 이용한 피부재생용 조성물 및 이의 용도 有权通过使用中和或分泌骨髓衍生的内皮祖细胞（CB-EPCS）进行皮肤再生的组合物及其用途
公开(公告)号：KR1020100114729A
公开(公告)日：2010-10-26
申请号：KR1020090033249
申请日：2009-04-16
Applicant: (주)차바이오텍
CPC classification number: A61K35/51 , A61K8/981 , A61K38/1808 , A61K38/1825 , A61K38/1866 , A61Q19/08 , C07K14/485 , C07K14/49 , C07K14/503 , C12N5/0692
Abstract: PURPOSE: A composition using umbilical cord blood stem cell-derived blood vessel precursor cells culture medium or secretion is provided to use as a therapeutic agent and to prevent skin aging. CONSTITUTION: A skin regenerative composition contains umbilical cord blood stem cell-derived blood vessel formation precursor cell culture medium, culture secretion, or concentrated liquid as an active ingredient. The umbilical cord blood stem cells are human umbilical cord blood stem cells. The composition further contains biocompatible histotechnology material. The composition is used for cosmetic product for preventing skin aging. A method for wound healing comprises: a step of isolating and culturing umbilical cord blood stem cell-derived blood vessel precursor cells; a step of removing the precursor cells to prepare culture medium or secretion; and a step of transplanting the culture medium or secretion to the skin of mammal except for human.
Abstract translation: 目的：提供使用脐带血干细胞衍生的血管前体细胞培养基或分泌物的组合物作为治疗剂并防止皮肤老化。 构成：皮肤再生组合物含有脐带血干细胞衍生的血管形成前体细胞培养基，培养物分泌物或浓缩液体作为活性成分。 脐带血干细胞是人脐带血干细胞。 组合物还含有生物相容的组织技术材料。 该组合物用于防止皮肤老化的化妆品。 一种伤口愈合方法，包括：分离培养脐带血干细胞来源的血管前体细胞的步骤; 去除前体细胞以制备培养基或分泌物的步骤; 以及将培养基或分泌物移植到除人之外的哺乳动物皮肤的步骤。
-
公开(公告)号：KR101972766B1
公开(公告)日：2019-04-29
申请号：KR1020120041753
申请日：2012-04-20
Applicant: (주)차바이오텍 , 차의과학대학교 산학협력단
IPC: C12N5/0735 , C12N5/074 , C12N15/86
-
-
-
-
-
-
-
-
-
Search Results
61
records
(took 0.03 seconds)
